Clinical trial · Interventional
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
Randomized Trial of a Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
NCT03310918CI-TRIAL-00107417active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is evaluating the impact a collaborative palliative care and oncology team will have on end-of-life outcomes, quality of end-of-life care, and the quality of life, symptoms, and mood of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Palliative Care | Other | — | UNRESOLVED |
| Standard Leukemia care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Collaborative palliative and oncology care
- description
- * 1st palliative care visit within 30 days of randomization in the outpatient or hospital * In outpatient setting: once monthly palliative care visits (or video/ or phone) * During hospital admissions: At least twice weekly palliative care visits
- interventionNames
- Other: Palliative Care
- Other: Standard Leukemia care
- type
- ACTIVE_COMPARATOR
- label
- Standard oncology care
- description
- * Palliative care consults only upon request * Standard oncology care
- interventionNames
- Other: Standard Leukemia care
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with AML receiving non-intensive therapy including hypomethylating agents, single-agent chemotherapy, targeted therapy agents, or single or combination non-intensive agents offered on a clinical trial, including the following populations: * Newly diagnosed AML * Relapsed AML * Primary refractory AML * The ability to provide informed consent * The ability to comprehend English or complete questionnaires with minimal assistance of an interpreter Exclusion Criteria: * Patients not receiving care at MGH * Patients receiving intensive chemotherapy (requiring 4-6 week hospitalization) * Patients receiving supportive care alone * Major psychiatric illness or co-morbid conditions prohibiting compliance with study procedures * Patients already receiving palliative care
References
Publications (1)
- DERIVEDJensen-Battaglia M, Sohn MB, Consagra W, Wang Y, Zhang Z, LoCastro M, Davis J, Buettner K, Mortaz S, El-Jawahri AR, Loh KP. Trajectories of physical well-being among adults with acute myeloid leukemia. Blood Adv. 2024 Jun 11;8(11):2612-2621. doi: 10.1182/bloodadvances.2023011804. PMID 38429079